RIEMSER Pharma GmbH to acquire Intrapharm Laboratories Ltd. in the pursuit of strengthening its international position within the specialty pharmaceutical sector Riems (Germany), Maidenhead (UK) – German specialty pharmaceutical company RIEMSER Pharma GmbH (“RIEMSER”) today announced the acquisition of British specialty pharmaceutical company Intrapharm Laboratories Ltd. (“Intrapharm”). With this add-on acquisition, RIEMSER marks another important milestone of its international growth strategy, significantly strengthening its position on the UK and Northern European markets. RIEMSER benefited from the strong support of Ardian in this transaction.
Acquired in 2009 by the present owners as a platform for growth, Intrapharm is a fast growing specialty pharmaceutical group marketing specialty pharmaceutical products with a primary focus on prescription-based and selected ‘over the counter’ (OTC) products. Intrapharm has since established itself as an important supplier to both the NHS and pharmacy wholesale markets ensuring the ongoing supply of pharmaceutical products with proven therapeutic value and medical need. Current products address therapeutic areas covering Oncology, Ophthalmology, Pain, Gastrointestinal and Dermatology.
The acquisition of Intrapharm strengthens the product offering and know-how of RIEMSER in the UK and it expands RIEMSER´s access to the Nordic and Irish market. Intrapharm management remains fully operational and strongly complements RIEMSER’s expertise and competences.
“I am very pleased for RIEMSER to join forces with Intrapharm, a very successful specialty pharmaceutical company to further strengthen our European growth strategy”, said Konstantin von Alvensleben, CEO of RIEMSER: “This acquisition successfully expands our geographic footprint and opens possibilities of developing our expertise in new niche
markets. In addition, Intrapharm contributes a very attractive product pipeline to the joint cohesive product portfolio.”
“We are very excited about the opportunity to jointly expand and accelerate our growth strategy under the umbrella of RIEMSER”, said Kevin James, co-owner of Intrapharm who will continue to serve as Director of the UK business.
Shafiq Choudhary, co-owner of Intrapharm will continue to serve as COO of the UK business.
About RIEMSER Pharma GmbH
RIEMSER Pharma GmbH, headquartered in Greifswald, Germany, is a midsize pharmaceutical company specialized on the marketing and sophisticated life cycle management of specialty drugs for treatment of highly complex and niche disease areas. RIEMSER targets European markets but its products are distributed worldwide by a wide-ranging partner network.
Ardian, founded in 1996 and led by Dominique Senequier, is an independent private investment company with assets of US$50bn managed or advised in Europe, North America and Asia. The company, which is majority-owned by its employees, keeps entrepreneurship at its heart and delivers investment performance to its global investors while fueling growth in economies across the world. Ardian’s investment process embodies three values: excellence, loyalty and entrepreneurship.
Ardian maintains a truly global network, with more than 380 employees working through twelve offices in Paris, London, Frankfurt, Milan, Madrid, Zurich, New York, San Francisco, Beijing, Singapore, Jersey and Luxembourg. The company offers its 433 investors a diversified choice of funds covering the full range of asset classes through Ardian Funds of Funds (comprising primary, early secondary and secondary activities), Ardian Private Debt, Ardian Direct Funds (comprising Ardian Mid Cap Buyout, Ardian Expansion, Ardian Growth and Ardian Co-Investment), Ardian Infrastructure, Ardian Real Estate and customized mandate solutions with Ardian Mandates.